Skip to main content
Equibles
SUPN logo

SUPN · Supernus Pharmaceuticals, Inc.

Track SUPN — free

Use SUPN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SUPN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$48.27 +1.12 (+2.38%) At close · Aug 14
Market Cap
$2.81B
Shares
58.13M

Supernus Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Supernus Pharmaceuticals, Inc. (SUPN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲19.5% $177.35M $1.75M '22 Q3 22-11-08 ▲5.2% $167.33M $25.48M '22 Q4 23-02-28 ▲0.8% $153.76M $16.95M '23 Q1 23-05-09 ▼20.3% $135.56M −$831,000 '23 Q2 23-07-24 ▼13.2% $153.88M −$15.98M '23 Q3 23-10-25 ▼1.8% $164.31M $1.18M '23 Q4 24-02-27 ▼6.6% $143.64M $124,000 '24 Q1 24-04-24 ▲24.2% $168.32M $19.92M '24 Q2 24-08-06 ▲14.2% $175.69M $38.50M '24 Q3 24-10-21 ▲6% $174.16M $15.33M '24 Q4 25-02-11 ▲4.3% $149.82M −$11.83M '25 Q1 25-04-23 ▼1.7% $165.45M $22.50M '25 Q2 25-07-22 ▲9.3% $192.10M −$45.12M '25 Q3 25-10-21 ▲21.5% $211.57M −$4.11M '25 Q4 26-02-24 ▲38.6% $207.71M −$2.29M '26 Q1 26-05-05 LATEST ▲32.4% $219.06M −$58.37M '26 Q2 26-08-03
Conference
Investor event
2026-08-03
Joint Supernus and Indivior Conference Call and Webcast
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-03
Supernus Pharmaceuticals, Inc. Q2 FY2026 Earnings Call
Revenue
$219.06M
▲ 32.4% YoY
Diluted EPS
$-1.01
▼ 352.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Supernus Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone Onapto/Oxtellar XR rebound and second supplier Quillivant/Kelbree ADHD franchise Zurzuvae collaboration growth
Revenue
$207.71M
▲ 38.6% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Supernus Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone Growth products portfolio ONAPCO launch and supply Calvary performance and gross-to-net
Revenue
$211.57M*
▲ 21.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-21
Supernus Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Revenue
$192.10M
▲ 9.3% YoY
Diluted EPS
$-0.80
▼ 215.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-22
Supernus Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Revenue
$165.45M
▼ 1.7% YoY
Diluted EPS
$0.40
▲ 11.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Supernus Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Revenue
$149.82M
▲ 4.3% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Supernus Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone Qelbree growth and label update ONAPGO launch Corporate development and financial strength
Revenue
$174.16M*
▲ 6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-21
Supernus Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Revenue
$175.69M
▲ 14.2% YoY
Diluted EPS
$0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Supernus Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Revenue
$168.32M
▲ 24.2% YoY
Diluted EPS
$0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Supernus Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Revenue
$143.64M
▼ 6.6% YoY
Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Supernus Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Revenue
$164.31M*
▼ 1.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Supernus Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$153.88M
▼ 13.2% YoY
Diluted EPS
$-0.29
▼ 1066.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-24
Supernus Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$135.56M
▼ 20.3% YoY
Diluted EPS
$-0.02
▼ 114.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Supernus Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$153.76M
▲ 0.8% YoY
Diluted EPS
$0.29
▼ 32.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Supernus Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$167.33M*
▲ 5.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Supernus Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$177.35M
▲ 19.5% YoY
Diluted EPS
$0.03
▼ 92.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Supernus Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$170.05M
▲ 20.3% YoY
Diluted EPS
$0.14
▼ 67.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Supernus Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$152.51M
▲ 16.5% YoY
Diluted EPS
$0.43
▲ 290.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Supernus Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$159.05M*
▲ 10.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Supernus Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$148.46M
▼ 4.3% YoY
Diluted EPS
$0.40
▼ 45.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Supernus Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$141.33M
▲ 11.5% YoY
Diluted EPS
$0.43
▼ 33.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Supernus Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$130.93M
▲ 37.9% YoY
Diluted EPS
$0.11
▼ 72.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Supernus Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Revenue
$143.56M*
▲ 42.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Supernus Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Revenue
$155.13M
▲ 51.9% YoY
Diluted EPS
$0.74
▲ 37% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Supernus Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Revenue
$126.73M
▲ 21% YoY
Diluted EPS
$0.65
▲ 6.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Supernus Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Revenue
$94.98M
▲ 11.1% YoY
Diluted EPS
$0.40
▲ 17.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Supernus Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Revenue
$100.45M
▼ 13.4% YoY
Diluted EPS
$0.62
▲ 29.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1356576 CUSIP 868459108 13F (30d) 307 filings 303 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)